Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 The neurotoxicity of misonidazole and its relationship to dose, half-life and concentration in the serum.

Literature DB >> 209808

The neurotoxicity of misonidazole and its relationship to dose, half-life and concentration in the serum.

M E Saunders, S Dische, P Anderson, I R Flockhart.

Abstract

Misonidazole has been given to a total of 87 patients. Neurotoxicity has occurred--convulsions with the higher doses and peripheral neuropathy with the lowern ones. The data from 34 patients receiving 4--7 doses has been analysed. Peripheral neuropathy is related to the total tissue exposure. By monitoring serum levels and controlling the total dose given, convulsions are avoidable and peripheral neuropathy restricted to a low and acceptable level.

Entities: Chemical Disease Species

Mesh：

Substances：

Year: 1978 PMID： 209808 PMCID： PMC2149393

Source DB: PubMed Journal: Br J Cancer Suppl ISSN： 0306-9443

3 in total

1. Clinical testing of the radiosensitiser Ro-07-0582. I. Dose tolerance, serum and tumour concentrations.

Authors: A J Gray; S Dische; G E Adams; I R Flockhart; J L Foster
Journal: Clin Radiol Date: 1976-04 Impact factor: 2.350

2. Serum concentration measurements in man of the radiosensitizer Ro-07-0582: some preliminary results.

Authors: J L Foster; I R Flockhart; S Dische; A Gray; I Lenox-Smith; C E Smithen
Journal: Br J Cancer Date: 1975-06 Impact factor: 7.640

3. Clinical testing of the radiosensitizer Ro 07-0582: experience with multiple doses.

Authors: S Dische; M I Saunders; M E Lee; G E Adams; I R Flockhart
Journal: Br J Cancer Date: 1977-05 Impact factor: 7.640

3 in total

17 in total

Review 1. Pharmacokinetic drug interactions with phenytoin (Part II).

Authors: R L Nation; A M Evans; R W Milne
Journal: Clin Pharmacokinet Date: 1990-02 Impact factor: 6.447

2. Misonidazole neuropathy. A prospective study.

Authors: B Melgaard; O Køhler; H Sand Hansen; J Overgaard; J Munck-Hansen; O B Paulson
Journal: J Neurooncol Date: 1988-11 Impact factor: 4.130

3. No significant effect of metoclopramide on misonidazole elimination in man.

Authors: K M Williams; E J Begg; D N Wade; K O'Shea
Journal: Br J Clin Pharmacol Date: 1983-03 Impact factor: 4.335

Review 4. Clinical results of hypoxic cell radiosensitisation from hyperbaric oxygen to accelerated radiotherapy, carbogen and nicotinamide.

Authors: M Saunders; S Dische
Journal: Br J Cancer Suppl Date: 1996-07

The neurotoxicity of misonidazole and its relationship to dose, half-life and concentration in the serum.

1. Clinical testing of the radiosensitiser Ro-07-0582. I. Dose tolerance, serum and tumour concentrations.

2. Serum concentration measurements in man of the radiosensitizer Ro-07-0582: some preliminary results.

3. Clinical testing of the radiosensitizer Ro 07-0582: experience with multiple doses.

Review 1. Pharmacokinetic drug interactions with phenytoin (Part II).

2. Misonidazole neuropathy. A prospective study.

3. No significant effect of metoclopramide on misonidazole elimination in man.

Review 4. Clinical results of hypoxic cell radiosensitisation from hyperbaric oxygen to accelerated radiotherapy, carbogen and nicotinamide.

Review 5. Nanoparticles for Targeting Intratumoral Hypoxia: Exploiting a Potential Weakness of Glioblastoma.

Review 6. Molecular imaging of hypoxia in non-small-cell lung cancer.

Review 7. Prevention and management of drug-induced peripheral neuropathy.

8. Evaluation of Optimal Post-Injection Timing of Hypoxic Imaging with ¹⁸F-Fluoromisonidazole-PET/CT.

9. Effects on tumour microcirculation in mice of misonidazole and tumour necrosis factor plus hyperthermia.

10. A biochemical method for assessing the neurotoxic effects of misonidazole in the rat.